跳至主要内容
临床试验/CTRI/2023/12/060436
CTRI/2023/12/060436招募中3 期

A prospective, comparative, randomised study on efficacy, safety and tolerability of topical tofacitinib vs topical tofacitinib with puvasol in the management of vitiligo. - NI

Dr Rohini Rathod0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)Patients who are clinically diagnosed cases of vitiligo
  • 2)Both sexes – males and females
  • 3)Age – above 12 years to 60 years
  • 4)Body surface area involving the depigmented patches of less than 10%
  • 5)Depigmented patches in exposed areas of the body

排除标准

  • 1)Patients having vitiligo patches in more than 10% BSA and having patches over flexure areas and genitals
  • 2)Patients with active or latent TB
  • 3)Patients with anaemia (Hb < 9g/dl) ,liver diseases, kidney disease, GI disease (diverticulitis, perforation ,ulcers ) , respiratory disease (ILD , COPD, pulmonary edema)
  • 4)Patients with malignancies or lymphoproliferative disorders
  • 5)Patients on potent immunosuppresants, biological DMARDS , H/O organ transplant
  • 6)Patients with deranged lipid profile
  • 7)H/O recent live vaccination
  • 8)Age less than 12 years, pregnancy and lactation
  • 9)Family history of melanoma/non melanoma skin cancers
  • 10)People suffering from photosensitivity disorders

研究者

发起方
Dr Rohini Rathod

相似试验

A comparative study on efficacy, safety and... | 临床试验